AUTHORS
Katherine Gamel Atkinson, DO, Andrew McKeithan Brown, MD2, Calvin Widholm3, Georgio Medawar, MD4, Stephanie Begley, MS5, Joshua F. Zeidner, MD6, David Swoboda, MD7, Brittany Knick Ragon, MD8, Alexander Coltoff, MD9
AFFILIATIONS
1 Medical University of South Carolina, Charleston, South Carolina, United States
2 Medical University of South Carolina, Charleston, South Carolina, United States
3 Medical University of South Carolina, Charleston, South Carolina, United States
4 Medical University of South Carolina, Charleston, South Carolina, United States
5 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
6 University of North Carolina, Chapel Hill, North Carolina, United States
7 Tampa General Hospital, Tampa, Florida, United States
8 Atrium Health Levine Cancer Institute/Wake Forest University School of Medicine, Charlotte, North Carolina, United States
9 Medical University of South Carolina, Charleston, South Carolina, United States
ABSTRACT
Introduction:
FLT3-mutant AML has a poor prognosis, particularly in the relapsed/refractory (R/R) setting. Gilteritinib, a type I FLT3 inhibitor (FLT3i), is approved as monotherapy in R/R FLT3-mutant AML based on results from the phase III ADMIRAL trial (Perl et al, NEJM 2019). However, outcomes remain poor in patients treated with gilteritinib with response rates ~40% and median overall survival <9 months. Clinical trials exploring triplet regimens of a hypomethylating agent (HMA), venetoclax, and a FLT3i for R/R FLT3-mutant AML have yielded promising clinical outcomes (Short et al, JCO 2024), but real-world data regarding this approach is limited. We conducted a multi-center, retrospective review of HMA + venetoclax + FLT3i in R/R FLT3-mutant AML.
Methods:
We retrospectively identified 21 patients ≥ 18 years of age with R/R FLT3-mutant AML treated with HMA + venetoclax + FLT3i between 6/2017 and 9/1/2025 from 4 participating centers. Data collected included disease characteristics (diagnostic subtype, cytogenetics, ELN 2022 and 2024 risk, co-mutations), prior lines of therapy and treatment strategies, response and treatment-related toxicities. The primary outcome of interest was the rate of complete remission (CR) or CR with incomplete hematologic recovery (CRi). Secondary outcomes included overall survival (OS), event-free survival (EFS), leukemia-free survival (LFS), and rate of hematopoietic stem cell transplant (HSCT). Median follow-up for this cohort was estimated using the reverse Kaplan-Meier method. Survival outcomes were estimated using Kaplan-Meier methodology.
Results:
Median follow-up was 22.3 months (95% CI, 10.4 - NR). Median age at diagnosis was 64 years (range 36–82 years) and 52% of patients were female. AML was de novo in 84.2%, secondary in 10.5%, and therapy-related in 5.3%. Cytogenetics were normal in 60% of patients with none having a complex karyotype. FLT3 mutation type was ITD in 76.2%, TKD in 19.0%, and both in 4.8%. By ELN 2022 criteria, 57% were intermediate risk and 43% were poor risk. By ELN 2024 criteria, all patients were intermediate risk. Common additional somatic mutations included NPM1 (50%), DNMT3A (29%), splicing-gene mutations (43%), IDH1/2 (14%), RUNX1 (26%), and RAS-pathway mutations (15%). The median number of prior lines of therapy was 1 (range 1–6), with 76% of patients having prior HMA exposure, 38% having prior venetoclax exposure and 62% having prior FLT3i exposure (77% of whom received midostaurin, and 7.7% of whom received gilteritinib). Two patients (9.5%) underwent a prior HSCT. The most common prior induction therapies were 7+3 (57% of patients) and HMA + venetoclax (29% of patients).
HMA in cycle 1 of triplet therapy was decitabine in 71% and azacitidine in 29% of patients; Cycle 1 FLT3i used included gilteritinib in 62.0%, quizartinib in 33.3% and midostaurin in 4.8%. Response rates after cycle 1 included: CR = 29%; CR/CRi = 62%; Refractory= 33% and 1 patient being non-evaluable. Best response to triplet-based therapy was CR in 43% of patients and CR/CRi in 67%, achieved after a median of 1 cycle (range 1–4).
Bloodstream/biopsy-proven infection occurred in 11% of patients and re-hospitalization occurred in 1 of 15 (6.7%) of patients treated at least partially as an outpatient during cycle 1 (5 patients were hospitalized for all of cycle 1 and one patient had missing data). Ten patients (48%) were bridged to HSCT at a median of 111 days (range, 44-307 days) from the start of cycle 1 of triplet therapy. No patient who proceed to HSCT had experienced relapse at their last known follow-up. Four patients (28.6%) relapsed, none of whom had received HSCT. The median OS of the entire cohort was 16.5 months (95% CI, 9.65 months – NR), median EFS was 8.4 months (95% CI, 0.71 months – NR), and median LFS was not reached (95% CI, 6.58 months – NR). Median follow-up of the population successfully bridged to HSCT was 10.4 (95% CI, 9.3 - NR), median OS was not reached in the cohort.
Conclusion:
In this cohort of heavily pretreated R/R FLT3-mutant AML, in which the majority of patients had prior FLT3i exposure, HMA + venetoclax + FLT3i produced encouraging response rates with a manageable toxicity profile and enabled HSCT in nearly half of patients. These real-world findings support further prospective evaluation of this triplet as salvage therapy and a potential bridging strategy in the R/R setting, particularly among FLT3i-exposed patients where treatment options remain limited.
DISCLOSURES
Katherine Gamel Atkinson, DO: No relevant conflicts of interest to declare.